Drug Trial Radar · NCT00163449
Efficacy and Safety of Ciclesonide in Preschool Children With Asthma (2 to 6 Years) (BY9010/M1-207)
Last checked: Nov 19, 2026Latest source record: Dec 8, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,000
Planned (sponsor's estimate)
Start
Nov 2005
Primary completion
Nov 2006
Study completion May 2007
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Sep 14, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Who can join
- All sexes, from 2 years, up to 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the present study is to compare the efficacy of inhaled ciclesonide in pre-school children. Ciclesonide will be inhaled once daily, using one of three dose levels and tested versus placebo. The study duration consists of a baseline period (2 to 4 weeks) and a treatment period (24 weeks). The study will provide further data on safety and tolerability of ciclesonide.
Conditions
- Asthma
Interventions
CiclesonideDrug
Efficacy and Safety of Ciclesonide
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- time to first moderate or severe asthma exacerbation.Time frame: 24 weeks
Locations
96 sites in 9 countries. Site status is shown where the registry gives one.
Altana Pharma/Nycomed
Campinas - SP, Brazil
Altana Pharma/Nycomed
Curitiba-PR, Brazil
Altana Pharma/Nycomed
Paraná, Brazil
Altana Pharma/Nycomed
Pinheiros Sao Paulo - SP, Brazil
Altana Pharma/Nycomed
Porto Alegre-RS, Brazil
Altana Pharma/Nycomed
Porto Alegre-RS, Brazil
Altana Pharma/Nycomed
Recife-PE, Brazil
Altana Pharma/Nycomed
Rio de Janeiro-RJ, Brazil
Altana Pharma/Nycomed
Rio Grande, Brazil
Altana Pharma/Nycomed
Salvador - Bahia, Brazil
Altana Pharma/Nycomed
Santo André-SP, Brazil
Altana Pharma/Nycomed
São Paulo, Brazil
Altana Pharma/Nycomed
São Paulo, Brazil
Altana Pharma/Nycomed
São Paulo, Brazil
Altana Pharma/Nycomed
São Paulo, Brazil
Altana Pharma/Nycomed
Sao Paulo - SP, Brazil
Altana Pharma/Nycomed
Sao Paulo-SP, Brazil
Altana Pharma/Nycomed
São Paulo-SP, Brazil
Altana Pharma/Nycomed
Berlin, Germany
Altana Pharma/Nycomed
Cologne, Germany
Altana Pharma/Nycomed
Dresden, Germany
Altana Pharma/Nycomed
Düsseldorf, Germany
Altana Pharma/Nycomed
Frankfurt, Germany
Altana Pharma/Nycomed
Heidelberg, Germany
Altana Pharma/Nycomed
Mannheim, Germany
Altana Pharma/Nycomed
München, Germany
Altana Pharma/Nycomed
Rosenheim, Germany
Altana Pharma/Nycomed
Wesel, Germany
Altana Pharma/Nycomed
Wiefelstede, Germany
Altana Pharma/Nycomed
Baja, Hungary
Altana Pharma/Nycomed
Budapest, Hungary
Altana Pharma/Nycomed
Budapest, Hungary
Altana Pharma/Nycomed
Budapest, Hungary
Altana Pharma/Nycomed
Debrecen, Hungary
Altana Pharma/Nycomed
Jászberény, Hungary
Altana Pharma/Nycomed
Kaposvár, Hungary
Altana Pharma/Nycomed
Kiskunhalas, Hungary
Altana Pharma/Nycomed
Miskolc, Hungary
Altana Pharma/Nycomed
Mosdós, Hungary
Altana Pharma/Nycomed
Mosonmagyaróvár, Hungary
Showing 40 of 96 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.